Optimize your cell line strategy for better viral vector production
Two cell line technologies. One integrated AAV
manufacturing portfolio.
Fill out the form to request more information or to talk to a cell line specialist
Beyond supporting your gene therapy processes with our technology and application knowledge, we're passionate about advancing solutions in areas where the status quo isn’t good enough.
The HEK293-based ELEVECTA™ cell line portfolio combines innovative design and deep expertise to deliver transient and stable producer options that provide competitive performance, high quality, and flexibility for your viral vector production.
- Fit for purpose: Choose the option that makes sense for your stage, asset mix, and organizational goals.
- Batch-to-batch consistency: Reduce variability and improve reproducibility in your manufacturing process.
- Scalable performance: Optimized for seamless scale-up from research to clinical and commercial production.
- Enhanced product quality: Minimize host cell DNA inside capsids, which is resistant to nucleases.
- Regulatory confidence: Benefit from a comprehensive suite of regulatory support services designed to expedite your success in advancing to and through clinical trials.
FDA-recognized innovation
The ELEVECTA™ transient cell line has received an Advanced Manufacturing Technology (AMT) designation from the FDA for its innovative AAV manufacturing approach. This designation enables earlier, more structured FDA engagement, reduces CMC uncertainty, and supports consistent product quality, including lower encapsidated host cell DNA.
Fast-track your therapeutics with our process development services
Our Fast Trak™ process development services can help get your next-generation therapeutics to market faster. With more than 35 years of experience, we can assist in developing upstream and downstream processes as you move towards adopting a new cell line.
- Development of an optimal upstream transient transfection process from shake-flasks to small-scale bioreactors.
- Process development from benchtop bioreactor to 50 L bioreactor including downstream process development, optimization and characterization.
- Product characterization analytics included (titer, full:empty, etc.).
ELEVECTA™ transient cell line
Preserves flexibility while delivering excellent performance and quality - all aimed at quickly advancing candidates to clinical trials.
- Excellent performance: Achieve high titers of infectious virus, which you can boost further by using enhancers.
- Enhanced product quality: Minimize DNase-resistant host cell DNA inside capsids.
- Innovative: Access advances in cell line engineering across the entire portfolio to support transition between cell lines.
- Collaborative: Benefit from a comprehensive suite of regulatory support services.
ELEVECTA™ stable producer cell line 2.0
Contains all genes to produce AAV; simply induce. The result is a simplified, robust upstream process that easily scales to treat hundreds of thousands.
- Simplified manufacturing workflow: Single‑step induction replaces complex transfection—just add inducer to start production, cutting complexity and timelines.
- Enhanced product quality: Reduced encapsidated host cell DNA.
- Scalable from bench to production: Consistent, high‑quality AAV output from bench scale through large‑scale manufacturing.
- Enhanced reproducibility: Reliable, batch‑to‑batch AAV production with documented lineage.
- Lower cost of goods: Eliminates plasmids and transfection reagents while simplifying operations to reduce manufacturing costs.
